Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$12B
P/E ratio
23×
Div yield
—
EPS (TTM)
$2.05
Profit margin
22%
Rev. growth
+9%
Revenue
$2.3B
Free cash flow
$0.6B
In plain English
Exelixis is an oncology biopharma built almost entirely on one molecule — cabozantinib, sold as CABOMETYX — a kinase inhibitor for kidney, liver and thyroid cancer. It sells the drug itself in the US, collects royalties from Ipsen and Takeda everywhere else, and is betting its future on a next-generation successor, zanzalintinib.
In simple terms
One molecule, many hands
Exelixis discovers cabozantinib, has contract manufacturers make it, and sells it as CABOMETYX in the US — while Ipsen and Takeda sell it abroad and BMS, Merck and Roche supply the immunotherapies it's combined with.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.